Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vermillion has received a patent for the discovery of novel forms of brain natriuretic peptide, which could potentially improve upon the current standard of care in diagnosing and treating cardiovascular disease, from the US Patent Office.
Subscribe to our email newsletter
The patent also covers the measurement of the new modifications of brain natriuretic peptide by a variety of methods, including SELDI (surface enhanced laser desorption/ionization) mass spectrometry – which was used to discover these specific forms – and other immunoassay approaches.
The company believes that the discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to stratify patients at risk for cardiovascular disease, including stroke and congestive heart failure.
Eric Fung, chief scientific officer of Vermillion, said: “We look forward to continuing to build our solid pipeline of potential biomarkers to aid in the diagnosis of serious, debilitating conditions.”